DHT.health recognised among Grant Thornton’s Top 100 “Ones to Watch” in the UK Pharma Services Sector

We’re proud to share that DHT.health has been recognised in Grant Thornton’s Pharma Services: Ones to Watch 2025, a report celebrating the UK’s top privately owned pharma services companies driving innovation, impact, and progress across the life sciences sector.

The report highlights organisations making exceptional contributions to the pharmaceutical ecosystem, from Contract Research and Development to Market Access, Health Economics and Outcomes Research (HEOR), and Real-World Evidence (RWE). It celebrates companies combining scientific rigour, creativity, and purpose to strengthen the bridge between healthcare research and societal benefit.

We are honoured to receive this recognition of the hard work being done by our people and our partners. We also want to use this achievement to reaffirm that our purpose is to serve people living with rare and underserved diseases, their caregivers, families, and the communities that support them.

Every project we deliver, every dataset we generate, and every partnership we build is guided by this principle. We are committed to working hand in hand with patient communities and advocacy groups so that their experiences, perspectives, and unmet needs continue to shape the evidence that drives progress.

We extend our heartfelt thanks to:

• The partners and collaborators who share our mission to improve outcomes in rare and underserved conditions.

  
  

• The patients and caregivers who have had the courage to share their stories, helping bridge the gap between therapeutic innovation and real-world need.

As we celebrate this recognition, we do so with gratitude and renewed purpose, continuing to build on our efforts, deepen collaboration, and drive meaningful change for the communities we exist to serve.

Thank you DHT.health

See the report here: https://www.grantthornton.co.uk/insights/pharma-services-ones-to-watch-2025/